Company Overview

 

The Company


Adynxx (A - dȳ - nix), located in San Francisco, California, is a clinical-stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.

 

Product Science


Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at thetime of surgery. Adynxx has completed Phase 1 and Phase 2 clinicals trial of AYX1.  Additional compounds targeting a range of intractable neuropathic and inflammatory pain syndromes are in the pre-clinical stage.